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OBJECTIVES: The aim of this study was to investigate the activities of serum paraoxonase and arylesterase in patients with an-
kylosing spondylitis with respect to those of healthy controls, to assess whether these enzyme levels are related to disease activity 
and functional capacity.
METHODS: The study included 32 patients with ankylosing spondylitis whose diagnoses were made according to the modified 
New York criteria as well as 25 healthy controls matched for age and sex. The Bath Ankylosing Spondylitis Disease Activity Index 
and the Bath Ankylosing Spondylitis Functional Index were applied to the ankylosing spondylitis patients. As laboratory parameters, 
the erythrocyte sedimentation rate and serum C-reactive protein level were measured in patients and control subjects. Paraoxonase 
and arylesterase enzyme activities were measured using appropriate methods.
RESULTS: No statistically significant differences (p>0.05) were found between the ankylosing spondylitis patients and controls in 
terms of serum paraoxonase or arylesterase levels. Furthermore, there was no correlation between clinical and laboratory parameters 
in patients with ankylosing spondylitis.
CONCLUSION: Serum paraoxonase and arylesterase levels in ankylosing spondylitis patients may not differ from those of healthy 
controls, and there is no significant correlation between antioxidant parameters and the Bath Ankylosing Spondylitis Disease Activ-
ity Index or Bath Ankylosing Spondylitis Functional Index scores in ankylosing spondylitis patients. Further research is needed to 
provide deeper understanding of this disease.
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INTRODUCTION
Ankylosing spondylitis (AS), an inflammatory arthritis of 
the spine, is the prototype HLA-B27-associated seronegative 
spondylarthritis.1 Although several studies have examined 
the pathogenesis of AS, the disease is not yet completely 
understood. Multifactorial mechanisms are believed to be 
responsible for the etiopathogenesis of AS.
Paraoxonase (PON), an enzyme produced by the liver, 
is associated with high-density lipoprotein particles and is 
known to have an antioxidant function.2-4 In humans, the 
PON gene family has three members (PON1, PON2, and 
PON3) that are located on chromosome 7q21.3-22.1.5 The 
physiological roles and natural substrates of these enzymes 
are not well known.6 PON1 has three known enzymatic 
molecules, including PON, arylesterase (ARE), and 
dyazoxonase. PON1 hydrolyzes organophosphates such as 
paraoxon, hydrolyzes aromatic esters such as phenylacetate, 
and also decreases the accumulation of lipid peroxidation 
products.7 
ARE, a thiol enzyme, is reactivated by 2-mercaptoethanol 
and cysteine but not by reduced glutathione. ARE acts on 
phenyl acetate to release phenol, which can produce a stable 176
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indophenol dye with 4-aminoantipyrine and potassium 
ferricyanide.8 Human serum PON1 and ARE are both esterase 
enzymes that have lipophilic antioxidant characteristics.9 
These enzymes play a role in decreasing oxidative stress. 
PON1 in particular is an important endogenous free radical 
scavenging system in the human body.10 Serum PON1 acts 
in conjunction with ARE to function as a single enzyme.6,11
Recently, a number of studies investigated serum PON 
and ARE activities in response to inflammatory arthritic 
conditions such as rheumatoid arthritis (RA), psoriasis, 
and systemic lupus erythematosus (SLE) with conflicting 
results.2,12-17 To the best of our knowledge, serum PON 
and ARE activities have not previously been assessed in 
patients with AS. Therefore, the aim of the present study 
was to assess whether PON and ARE levels may be related 
to disease activity and functional capacity in AS patients.
MATERIALS AND METHODS
Thirty-two patients with AS and 25 sex- and age-
matched healthy controls were enrolled in the study. The 
diagnosis of AS was made according to the modified New 
York criteria.18 Patients with AS consumed non-steroidal 
anti-inflammatory drugs, but no TNF-a inhibitory drugs, 
during this study. In addition, five patients with peripheral 
involvement were taking sulphasalazine. 
Controls  had  no  systemic  disease.  None  of  the 
participants in the present study was obese, nor were any 
of them taking lipid lowering agents or antioxidant drugs. 
None of the patients or controls was a smoker or consumed 
alcohol. 
We used the Bath Ankylosing Spondylitis Disease 
Activity Index (BASDAI) and the Bath Ankylosing 
Spondylitis Functional Index (BASFI) questionnaires for 
clinical assessment of the patients with AS. These two self-
limited questionnaires are the gold standard for measuring 
disease activity and functional capacity in AS patients. The 
BASDAI consists of a 1 through 10 scale (one indicating no 
problem and 10 indicating the worst problem) that is used to 
answer six questions pertaining to the five major symptoms 
of AS (fatigue, spinal pain, joint pain, and enthesitis, as well 
as morning stiffness duration and severity).19 The BASFI also 
has a 1 through 10 scale (1 indicating easy and 10 indicating 
impossible) and consists of ten questions, eight of which 
relate to the functional capacity of patients and two of which 
relate to the patient’s ability to cope with everyday life.20
This study was performed in accordance with the 
ethical standards set by the Declaration of Helsinki and was 
approved by the local ethics committee.
Laboratory assessments: All participants were 
analyzed in terms of complete blood count and erythrocyte 
sedimentation rate (ESR), as well as C-reactive protein 
(CRP), serum PON, and ARE levels. All venous blood 
samples were obtained following an overnight fast. The 
serum was then separated from blood cells by centrifugation 
and immediately stored at -800C until analysis.
The ESR levels were determined according to the 
Westergren method. A nephelometric method was used for 
measuring CRP levels (Beckman Array Protein System, 
USA). 
Measurement  of  PON1  and ARE  activities: 
PON1 activities were measured using diethyl-0-p-
nitrophenylphosphate as a substrate. Assays were made 
without additional NaCl (baseline activity) and with 1 mol/L 
NaCl included in the assay buffer (salt-stimulated activity), 
by following the formation of p-nitrophenol (assessed by the 
absorbance at 405 nm) for 5 min. The assay buffer contained 
0.125 mol/L Tris-HCl (pH 8.5), 1.25 mmol/L CaCl2, and, for 
each set of assays, 6 mmol/L of a freshly prepared paraoxon 
(O,O-diethyl-0-p-nitrophenylphosphate; Sigma Chemical 
Co) substrate solution and 1 mol/L NaCl (pH 8.5). The 
paraoxon stock solution was handled very cautiously using 
protective measures. The assay tube contained 750 µL of 
Tris buffer, 50 µL of serum (diluted 1:2 with water), and 
200 µL of 6 mmol/L paraoxon. The enzymatic reaction was 
started at 37ºC by the addition of the substrate solution. 
Using a Techcomp 8500 II Spectrophotometer, absorbance 
was continuously monitored at 405 nm and 25ºC. One unit 
of PON1 activity was defined as the enzyme quantity that 
disintegrated 1 µmol of paraoxon substrate in 1 minute.21,22 
The percent stimulation of PON1 was calculated as follows:
[(PON1 activity with 1 mol/L NaCl)-(basal activity) / 
basal PON1 activity] x100.23
ARE activity was measured using phenylacetate as the 
substrate. The assay tube contained 750 µL of 0.1 mol/L 
Tris-HCl at pH 8.5, 1 mmol/L CaCl2, 125 µL of 12 mmol/L 
phenylacetate, and 125 µL of serum (diluted 1:10 with water 
). The increase in absorbance was continuously recorded at 
270 nm and 37ºC. The units were expressed as millimoles of 
phenylacetate hydrolyzed per minute.
Statistical analysis: The statistical analysis was 
performed  using  the  SPSS  11.0  package  program. 
Differences between groups were analyzed using the Mann-
Whitney U test. Correlation analyses were performed using 
Pearson’s correlation test. A p-value of less than 0.05 was 
considered to be statistically significant.
RESULTS
The AS group was comprised of 32 patients; nine were 
female and 23 male. The mean age of these patients was 33 
years (range 20-65), and the disease duration was 8.13 years 177
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(range 1-25). In the control group (n=25), seven healthy 
volunteers were female and the others male. The mean age 
of the control group was 30.28 years (range 20-56). There 
was no statistically significant difference between patients 
and controls with regard to demographic data (p>0.05) 
(Table 1). 
When laboratory findings were compared between 
the AS and control groups, the ESR but not CRP levels 
differed significantly between the AS and control group 
(p<0.05). When compared to the healthy controls, there 
was no statistically significant difference in serum PON 
or ARE levels for patients with AS (p>0.05) (Table 1). In 
addition to these findings, we found no correlations among 
BASDAI and BASFI scores, serum PON, or ARE values 
in the AS group in the present study. Finally, there were no 
statistically significant correlations between serum PON 
and ARE levels or demographic variables (e.g., gender or 
disease duration). 
DISCUSSION 
AS is a chronic, progressive inflammatory disease of 
unknown etiology. The inflammation primarily affects 
the axial skeleton, peripheral joints, and extra-articular 
structures. The pathophysiological basis of AS has not yet 
been well identified, but immunological mechanisms have 
been implicated.24 Various functions of neutrophils have been 
shown to be enhanced in AS; these stimulated neutrophil 
functions mediate oxidative stress, which may have an 
important role in the pathogenesis of AS.25-27 
Oxidative stress describes situations in which the 
production of damaging oxidants exceeds the organism’s 
capacity to neutralize them.26-28 A decisive role of oxidative 
stress in inflammatory diseases like AS has not yet been 
fully elucidated. However, reactive oxygen species produced 
by activated neutrophils during inflammatory reactions 
play important functions in the pathogenesis of many 
inflammatory diseases.24,29 Inflammatory reactions trigger 
oxidative stress that leads to increased oxidant levels, which 
in turn decrease the level of antioxidants. The antioxidant 
defense system is responsible for protecting cells against the 
potentially harmful effect of oxidizing agents 30,31 
In addition to these findings, a limited number of studies 
investigated the association between the pathogenesis of 
AS and oxidative stress. For example, Ozgocmen et al.32 
reported that oxidative stress and lipid peroxidation were 
accelerated in untreated patients with active AS but found 
no significant correlation between oxidant/antioxidant 
levels and disease activity. In another study, Karakoc and 
coworkers24 indicated that increased oxidant and decreased 
antioxidant capacity might be related to the pathogenesis of 
AS, but again no significant correlation between antioxidant/
oxidant parameters and disease activity was found. These 
results are in part also comparable to our findings in 
the present study. We found no statistically significant 
difference in antioxidant enzyme levels in AS patients 
upon comparison to healthy controls and also detected no 
significant correlation between antioxidant parameters and 
disease activity. 
However, various other reports in the medical literature 
have indicated alterations in serum PON and ARE activities 
for patients with different rheumatic diseases, such as 
RA, psoriasis, SLE, and Behcet’s disease.2,12-17 In many of 
these studies, PON and ARE activities were reported to 
be significantly lower in patients with rheumatic diseases 
than in healthy controls.2,12-16 In another study, Kiss and 
coworkers 16 indicated that ARE activity in patients was not 
different from that of controls, despite reduced PON activity 
Table 1 - Demographic data as well as clinical and laboratory findings in patients with AS and healthy controls
AS group Control group P values
Sex (male/female) (23-9) (18-7) ns
Age (years) 30 (20-65) 28 (20-56) ns
Disease duration (year) 6 (1-25) - -
PON (U/ml) 292096.6
(105083.5-979591.8)
320699.7
(101563.7-967930.0)
ns
ARE (mmol pha/min) 219847.3
(146564.9-952671.8)
197862.6
(102595.4-952671.8)
ns
ESR (mm/h) 16.5 (3-58) 10 (3-23) <0.05
CRP (mg/dl) 0.9 (0.3-2.9) 0.5 (0.3-1.1) ns
BASDAI 2.9 (0.2-6) - -
BASFI 1.0 (0.0-10) - -
AS: ankylosing spondylitis, ESR: erythrocyte sedimentation rate, CRP: C-reactive protein, PON: paraoxonase, ARE: arylesterase, BASDAI: Bath Ankylos-
ing Spondylitis Disease Activity Index, BASFI: Bath Ankylosing Spondylitis Functional Index. ns: not significant178
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in patients with SLE. In contrast, Toker et al.17 reported 
that serum PON1 and ARE activities were significantly 
higher in patients with psoriasis than in controls. Thus, the 
range of findings remains complicated and controversial. 
To the best of our knowledge, the present study is the first 
to assess serum PON and ARE activities in patients with 
AS. We found no significant difference in serum PON and 
ARE activities in patients with AS when compared to those 
of healthy controls. In addition, there was no significant 
correlation among antioxidant parameters, disease activity, 
or the patient’s functional ability.
CONCLUSIONS
Serum PON and ARE activities may be within normal 
ranges and may not be associated with disease activity and 
functional capacity in patients with AS. Further research is 
needed to provide a deeper understanding of this disease.
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